Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
Molecules · 24.07.2025 · 30 (15) · 3101
DOI: 10.3390/molecules30153101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 24.07.2025. Verfasst von Irena Philipova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bontchev Str. Bl. 9, 1113 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Metallocenes, Ferrous Compounds, Protein Kinase Inhibitors, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Fund, Bulgaria.
Abstract (Originalsprache)
Ferrocene (Fc), a redox-active organometallic scaffold, has attracted significant attention in medicinal chemistry due to its favorable physicochemical and pharmacological properties. The present study explores the therapeutic potential of novel Fc-functionalized analogues of imatinib and nilotinib, aimed at targeting BCR-ABL1+ chronic myeloid leukemia (CML) cells. A series of Fc-based derivatives (compounds 6, 9, 14, and 18) were synthesized by systematically substituting key pharmacophoric regions of the parent tyrosine kinase inhibitors with Fc units. The antiproliferative activity of these compounds was evaluated against four BCR-ABL1-positive leukemia cell lines (K-562, BV-173, AR-230, and LAMA-84), with imatinib serving as a reference drug. Biological assays revealed distinct structure–activity relationships. Compounds 6 and 9 demonstrated superior activity against the K-562 cell line, while compounds 14 and 18 exhibited enhanced potency and higher ligand efficiencies (LEs) against BV-173 and AR-230 cells compared to imatinib. Selectivity assays further indicated favorable toxicity profiles of compounds 9 and 14 toward malignant versus non-malignant cells. Molecular docking studies supported these findings, showing that Fc substitution alters binding interactions within the c-Abl kinase ATP-binding site while retaining key stabilizing contacts. Computationally predicted LEs showed strong correlation with experimental data, especially for K-562 and LAMA-84 cells, confirming the kinase as a relevant target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bontchev Str. Bl. 9, 1113 Sofia, Bulgaria.
- Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.
ORCID-Profile: Irena Philipova, Mariyana Atanasova, Rositsa Mihaylova, Stefan M Ivanov, Rumyana L Simeonova, Georgi Stavrakov
Förderung
- National Science Fund, Bulgaria
Zitieren
APA
Philipova, I., Atanasova, M., Mihaylova, R., Dailova-Barzeva, A., Ivanov, S. M., Simeonova, R. L., & Stavrakov, G. (2025). Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions. Molecules, 30(15), 3101. https://doi.org/10.3390/molecules30153101
Vancouver
Philipova I, Atanasova M, Mihaylova R, Dailova-Barzeva A, Ivanov SM, Simeonova RL, et al. Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions. Molecules. 2025;30(15):3101. doi:10.3390/molecules30153101
BibTeX
@article{Philipova2025,
author = {Philipova, Irena and Atanasova, Mariyana and Mihaylova, Rositsa and Dailova-Barzeva, Asine and Ivanov, Stefan M and Simeonova, Rumyana L and Stavrakov, Georgi},
title = {Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions},
journal = {Molecules},
year = {2025},
volume = {30},
number = {15},
pages = {3101},
doi = {10.3390/molecules30153101}
}
EUVIMED